DCprime announced the appointment of two highly-experienced industry veterans, Andrea van Elsas, Ph.D. and Hans Preusting, Ph.D., M.B.A, to its Supervisory Board.
Leiden, The Netherlands, April 25, 2019 – DCprime, the front-runner in the field of relapse vaccines, today announced the appointment of two highly-experienced industry veterans, Andrea van Elsas, Ph.D. and Hans Preusting, Ph.D., M.B.A, to its Supervisory Board. The newest members complement the existing Board, with Dharminder Chahal remaining Chairman and representing Van Herk Investments, DCprime’s primary shareholder.
“We continue to build DCprime at the corporate level and are excited to announce two valuable additions to our Supervisory Board,” commented Dharminder Chahal.
Erik Manting, CEO of DCprime, stated, “Both Andrea and Hans add tremendous expertise to our Board as we move forward with our clinical trials in AML as well as MDS and Multiple Myeloma soon. We are fortunate to have their experience and perspective as we continue to develop the novel class of relapse vaccines.”
Dr. van Elsas is currently Chief Scientific Officer of Aduro Biotech, Inc. He joined Aduro following the 2015 acquisition of BioNovion, a company he co-founded that was focused on the development of innovative therapeutic antibodies in the field of immuno-oncology. In addition, Dr. van Elsas is VP Research of AM Pharma, a company developing recombinant human Alkaline Phosphatase for inflammatory diseases, and he supports Gilde Healthcare as an Operational Partner in the evaluation of investment opportunities. He currently serves on the Board of Lava Therapeutics, and on the Scientific Advisory Board of InteRNA Technologies. He holds a Ph.D. in Immunology and Oncology from the University of Leiden.
Dr. van Elsas commented, “DCprime has a unique approach to cancer immunotherapy. I believe there is a great opportunity in using relapse vaccines in the therapeutic window DCprime has chosen, to prevent or delay tumor recurrence and transform the landscape of cancer care.”
Dr. Preusting is currently CEO of Synerkine Pharma and has previously served as the Chief Business Officer of uniQure. He was previously the Director of Process Development and Manufacturing at AMT, the predecessor of uniQure. Dr. Preusting also works as an independent consultant to several biotech companies. Dr. Preusting holds two patents and has published over 20 scientific articles. His expertise is focused in business development, product development and manufacturing using fermentation and cell culture techniques. He earned a Ph.D. in biochemistry and an M.B.A. from the Rotterdam School of Management.
Dr. Preusting added, “I had the opportunity to support a number of paradigm-changing approaches, such as gene therapy, throughout my career. I look forward to working with the DCprime team to help shape this new class of oncology vaccines and improve the survival of patients living with cancer.”
About DCprime
DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. Our lead product is a whole-cell based vaccine addressing blood cancers with a high risk of relapse. We are pursuing similar vaccination approaches for solid tumors. We believe relapse vaccines will improve survival by putting the patient’s immune system back in control. For more information, please visit: https://dcprime.com/
Contact Information:
DCprime BV
Dr. Erik Manting
CEO
Phone: +31713322627
Email: e.manting@dcprime.com
Media Contact:
Mario Brkulj or Nicholas Chang
MacDougall
Phone: +49 175 5711562 or +1 781 235 3060
E-Mail: dcprime@macbiocom.com
